LOXL4 Inhibitors
LOXL4 inhibitors belong to a distinctive class of chemical compounds designed to target and impede the activity of lysyl oxidase-like 4 (LOXL4), an enzyme that plays a crucial role in the extracellular matrix (ECM) remodeling and maintenance of tissue structure. LOXL4 is a member of the lysyl oxidase (LOX) family of enzymes, which are primarily responsible for catalyzing the cross-linking of collagen and elastin fibers in the ECM. The cross-linking process is essential for providing mechanical strength and stability to connective tissues such as skin, blood vessels, and organs. Inhibition of LOXL4, therefore, is of interest in various contexts, including pathological conditions where aberrant ECM remodeling is implicated, such as fibrosis and certain types of cancers.
LOXL4 inhibitors are designed to interact selectively with the active site of the LOXL4 enzyme, preventing its normal catalytic function. By disrupting the enzymatic activity of LOXL4, these inhibitors have the potential to modulate the deposition and organization of extracellular matrix components, which may have downstream effects on cell behavior, tissue architecture, and overall physiological homeostasis. The development of LOXL4 inhibitors represents a targeted approach to intervene in specific biological pathways associated with ECM remodeling, offering insights into potential strategies for addressing disorders characterized by dysregulated tissue structure and function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
3-Aminopropionitrile | 151-18-8 | sc-266473 | 1 g | $104.00 | ||
A nonspecific inhibitor of lysyl oxidase family proteins. It can prevent the cross-linking of collagen and elastin in the extracellular matrix by LOXL4. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
A derivative of febrifugine that inhibits the TGF-beta pathway. LOXL4 can be upregulated by TGF-beta, so inhibiting this pathway can indirectly inhibit LOXL4. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
An inhibitor of the TGF-beta receptor, preventing the activation of the TGF-beta pathway. This can indirectly inhibit LOXL4 expression. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
Another inhibitor of the TGF-beta receptor. It can reduce the upregulation of LOXL4 caused by TGF-beta signaling. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
An activator of soluble guanylate cyclase that also inhibits hypoxia-inducible factor (HIF), which can upregulate LOXL4 under hypoxic conditions. | ||||||
PX-478 | 685898-44-6 | sc-507409 | 10 mg | $175.00 | ||
An inhibitor of HIF-1alpha, the main component of HIF. By inhibiting HIF-1alpha, it can inhibit the upregulation of LOXL4 under hypoxic conditions. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
A disruptor of HIF-1alpha and p300 interaction, which is necessary for HIF-1alpha's activity. By blocking this interaction, it can inhibit the upregulation of LOXL4 under hypoxic conditions. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $166.00 | 4 | |
A quinoxaline antibiotic that inhibits HIF-1alpha's DNA-binding activity. By inhibiting HIF-1alpha, it can prevent the upregulation of LOXL4 under hypoxic conditions. | ||||||
2-Methoxyestradiol | 362-07-2 | sc-201371 sc-201371A | 10 mg 50 mg | $71.00 $288.00 | 6 | |
An inhibitor of angiogenesis that can inhibit HIF-1alpha. This can prevent the upregulation of LOXL4 under hypoxic conditions. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
A cardiac glycoside that inhibits HIF-1alpha. This can prevent the upregulation of LOXL4 under hypoxic conditions. | ||||||